RYTHM, Inc. (RYM)

RYTHM, Inc. is a brand-focused company in the hemp-derived cannabis space, owning and operating a portfolio of consumer brands including RYTHM, Señorita, incredibles, Beboe, and Dogwalkers. The company changed its name from Agrify Corporation in August 2025 and has shifted from being a vertically integrated hardware and farming operation to being primarily a brand and licensing business. The entire company is built on a single regulatory premise: that hemp-derived tetrahydrocannabinol (THC) products will remain legal at the federal level in the United States. If that premise fails, the business collapses.

What is the company actually doing?

RYTHM owns intellectual property — brand names, recipes, formulations — for consumer products made from hemp-derived THC. Rather than manufacturing or distributing itself, RYTHM licenses the brands to partners who handle production, bottling, warehousing, and retail placement. The company’s flagship beverage is Señorita THC Margaritas, which has secured placement in over 800 Circle K convenience stores across the United States, marking the largest convenience-store rollout of hemp THC beverages to date. The company also holds brands in edibles (incredibles), other beverages (RYTHM), and related products. Revenue comes from licensing fees, wholesale markups, and direct sales through its own retail and online channels.

This is a pure-play brand-licensing model. RYTHM is not growing hemp, not extracting cannabinoids, not bottling or distributing. It is holding intellectual property and collecting licensing fees from partners who do the work. The advantage is capital efficiency: the company does not need to invest in agriculture, manufacturing facilities, or logistics. The disadvantage is that RYTHM has no control over how its brands are executed, no inventory risk but also no margin upside from manufacturing or distribution, and complete dependence on the health and execution of its licensing partners.

How does RYTHM make money?

The company’s revenue comes from multiple streams within the hemp THC space. Licensing fees represent payments from manufacturing and distribution partners who produce and sell products under RYTHM’s brands. Wholesale revenue comes from direct sales to distributors and retailers who then resell to end customers. The company reported revenue of $13.3 million in Q1 2026, up 24% from the prior quarter, with gross profit of $10.4 million (a 78% gross margin — extraordinarily high for a consumer-products business, a consequence of the licensing and wholesale model requiring no manufacturing capex).

The margin profile reflects the capital-light nature of the business, but also its thinness. At $13 million in quarterly revenue, RYTHM is a micro-cap company operating in a category that is almost entirely unproven at scale. Growth depends entirely on retail placement and consumer demand for hemp THC products — categories that did not exist as mainstream retail products five years ago.

What is the fundamental risk?

The entire business is predicated on federal permission to sell hemp-derived THC. Current U.S. federal law treats hemp-derived THC products with significant ambiguity. The 2018 Farm Bill legalized hemp as an agricultural commodity and created a loophole: hemp-derived cannabinoids remain legal as long as they derive from federally approved hemp and are not explicitly prohibited. This has allowed companies to sell hemp THC beverages and edibles in states where cannabis remain prohibited, and in many states where state law is silent.

However, this loophole is under explicit threat. Congress has been considering amendments to the Controlled Substances Act that would explicitly prohibit hemp-derived THC products, closing the gap and making such products illegal at the federal level. RYTHM itself disclosed that there is a pending federal prohibition with a November 2026 effective date, which is already approaching. If Congress allows that prohibition to take effect without a carve-out or amendment, hemp THC products become illegal to manufacture, sell, and distribute nationwide. RYTHM’s entire business evaporates overnight. Investors in the company are betting that Congress either amends the law to permit hemp THC before November 2026, or that the prohibition is delayed, overturned, or not enforced with vigour. Any of those outcomes is possible, but none is guaranteed.

Why would Congress actually prohibit hemp THC?

There are two competing views. The cannabis industry has argued that hemp THC is a legitimate product that exists in a legal grey zone and should be explicitly permitted, since it comes from federally legal hemp. The broader policy community — including some federal agencies and public-health advocates — has argued that allowing an intoxicating product (THC gets consumers high) to be sold in every retail environment, with minimal regulation and no warning labels, is reckless. The FDA has never reviewed hemp THC products for safety. The hemp THC category has grown with almost no quality standards, no manufacturing oversight, and no medical claims evaluation. Products vary wildly in potency and purity. From a public-health and regulatory-clarity perspective, explicitly prohibiting the category until it can be properly regulated makes sense.

The political economy of the issue is genuinely unclear. Hemp farming interests, convenience-store chains, and the emerging hemp THC industry all have incentives to prevent a prohibition. Public-health groups, the DEA, and traditional cannabis advocates (some of whom view hemp THC as unfair competition) have incentives to push toward prohibition. The outcome will depend entirely on Congressional action, which is inherently unpredictable.

Is RYTHM exposed to any other risks?

Yes, though they are secondary to the regulatory risk. If hemp THC remains legal but becomes heavily regulated — requiring manufacturing standards, warning labels, age-gated sales, and regular testing — the cost of compliance could squeeze RYTHM’s licensing partners’ margins and reduce demand. Competition from branded cannabis companies in states with legal cannabis, and from alcohol and energy-drink makers in states without it, could limit growth. And execution risk exists: if RYTHM’s licensing partners fail to deliver quality products or fail to capture retail shelf space, the brands will not grow.

But all of those risks are negligible relative to the probability of a federal prohibition wiping out the entire category. The company’s value, from an investment perspective, is almost entirely a bet on Congressional action and regulatory forbearance.

How should an investor research RYTHM?

Read the company’s 10-K filing (SEC CIK 0001800637) and pay close attention to the risk-factor section, which will detail the pending prohibition and RYTHM’s assessment of the probability of Congressional action. Monitor Congressional calendars and any legislative proposals affecting hemp or THC. Follow reporting from cannabis-industry and public-policy publications about the trajectory of hemp THC regulation. Watch for any statements from federal agencies — the DEA, FDA, or HHS — that signal an official position on hemp THC enforcement.

Quarterly earnings calls will provide colour on retail placement, brand momentum, and licensing-partner health. But those are tactical. The strategic question is binary: will Congress permit hemp THC, or will it prohibit the category? RYTHM is a company built entirely on the affirmative answer to that question. If the answer shifts, the investment thesis collapses regardless of quarterly revenue growth.